Download MendeleyEngineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms.
Maxwell, J.W.C., Ripoll-Rozada, J., Mackay, A.S., Alwis, I., Ford, D.J., Trought, C.B.J., Santos, J.A., Smythe, R.E., Liu, J.S.T., Zuccolotto, Z., Schoenwaelder, S.M., Jackson, S.P., Pereira, P.J.B., Payne, R.J.(2025) Chem Sci 16: 18660-18672
- PubMed: 40959396
- DOI: https://doi.org/10.1039/d5sc04734j
- Primary Citation of Related Structures:
8RTN - PubMed Abstract:
Haematophagous organisms are a rich source of salivary anticoagulant polypeptides that exert their activity by blocking the catalytic site and one of two positively charged exosites on the host protease thrombin. Here, we describe a molecular engineering approach to hybridise post-translationally sulfated polypeptides from different blood-feeding organisms to enhance anticoagulant activity. This led to the discovery of a triply sulfated hybrid anticoagulant, XChimera, possessing fragments from flea, leech, and fly salivary polypeptides that exhibits femtomolar inhibitory activity against thrombin. The crystallographic structure of a complex of XChimera with thrombin shows that it displays a trivalent binding mode in which it simultaneously blocks three functional sites of the protease, the active site and exosites I and II. This trivalent chimera exhibited ultrapotent anticoagulant activity in a suite of in vitro clotting assays and was also shown to possess potent in vivo antithrombotic activity in a murine model of thrombosis.
- School of Chemistry, Faculty of Science, The University of Sydney NSW Australia richard.payne@sydney.edu.au.
Organizational Affiliation:
